Magnesium Status Detection Using DNA Methylation Biomarkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing magnesium deficiency, such as serum Mg levels and Mg tolerance tests, are inadequate due to their low sensitivity and specificity, impracticality, and inability to accurately measure overall body magnesium status, leading to misclassification and challenges in clinical and research settings.
Innovation Solution
The use of methylation biomarkers, specifically 5-hydroxymethylcytosine (5-hmC) and 5-methylcytosine (5-mC), differentiated through techniques like bisulfite treatment and TAB-Seq/TAB-Array protocol, to assess magnesium deficiency status in biological samples.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If serum Mg levels are used to diagnose magnesium deficiency, then the method is simple and non-invasive, but the sensitivity and specificity are low due to tight regulation of serum Mg concentrations
Solution Approach 1:
The patent uses DNA methylation biomarkers as an intermediary to indirectly assess magnesium status. Instead of directly measuring serum Mg (which is tightly regulated and doesn't reflect true body Mg status), the method measures methylation patterns in DNA that are influenced by magnesium deficiency, providing a more accurate diagnostic marker.
Solution Approach 2:
The patent replaces the traditional biochemical measurement approach (serum Mg levels) with an epigenetic measurement approach (DNA methylation analysis). This substitution allows for more sensitive detection of magnesium deficiency by measuring molecular changes in DNA rather than relying on tightly regulated serum concentrations.
2Measurement precision
If Mg tolerance tests are used to assess magnesium status, then the method provides more accurate measurement, but the procedure is impractical and complex requiring multiple urine samples and IV infusion
Solution Approach 1:
The patent extracts the essential information needed to assess magnesium status from the complex Mg tolerance test procedure. Instead of requiring multiple urine samples and IV infusion, the method extracts and measures specific DNA methylation biomarkers that reflect magnesium deficiency, simplifying the procedure while maintaining diagnostic accuracy.
Solution Approach 2:
The patent creates a molecular copy (DNA methylation pattern) that serves as a surrogate marker for magnesium status. This copy can be measured in blood or tissue samples without requiring the complex physiological maneuvers of the Mg tolerance test, providing an easier alternative that maintains diagnostic accuracy.
3Ease of operation
If a critical serum Mg value of 0.7 mmol/l is used for diagnosis, then the method is straightforward, but only 10% of patients with Mg deficiency are diagnosed due to false negatives
Solution Approach 1:
The patent changes the diagnostic parameter from serum Mg concentration to DNA methylation patterns. This parameter change allows for earlier and more accurate detection of magnesium deficiency, improving the identification rate from 10% to a significantly higher proportion of affected patients while maintaining diagnostic reliability.
Data Source
AI summary
The presently-disclosed subject matter includes methods for detecting methylation biomarkers in a biological sample from a subject in need of assessment for magnesium deficiency status, methods of diagnosing magnesium deficiency, methods of diagnosing magnesium insufficiency, methods of treating magnesium deficiency, methods of diagnosing magnesium insufficiency, and methods of preventing or reducing a risk of developing a condition linked to magnesium deficiency.